BioCentury
ARTICLE | Company News

BioAtla, F1 Oncology and SunTerra deal

January 13, 2017 7:58 PM UTC

BioAtla granted F1 Oncology exclusive, worldwide rights to IP for adoptive cellular therapy preparations and cancer treatments. The partners will aim to combine BioAtla's Conditionally Active Biologic (CAB) technology with F1's chimeric antigen receptor (CAR) T cell technology to develop adoptive cellular therapies, including CAR T treatments with lower on-target, off-tumor toxicity than existing therapies.

BioAtla will receive a majority, non-controlling stake in F1 Oncology and a time-limited option to acquire the company's remaining equity from its other investors. The partners will share revenues in China, including Hong Kong and Macau, and Taiwan. BioAtla will be eligible for mid-single-digit royalties elsewhere...

BCIQ Company Profiles

BioAtla Inc.

Exuma Biotech Corp.